Search
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...
Categories: P-glycoprotein inhibitorsDapoxetine
go.drugbank.com/drugs/DB04884InvestigationalDapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latenc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsVapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesTesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsOspemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Synonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAzimilide
go.drugbank.com/drugs/DB04957InvestigationalAzimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in th...
Synonyms: 1-((5-(P-CHLOROPHENYL)FURFURYLIDENE)AMINO)-3-(4-(4-METHYL-1-PIPERAZINYL)BUTYL)HYDANTOINCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesBanoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPlitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates